Terms: = Breast cancer AND PML, TRIM19, 5371, ENSG00000140464, MYL, PP8675, RNF71
101 results:
1. Immediate versus delayed breast reconstruction: Long-term follow-up on health-related quality of life and satisfaction with breasts.
Kuhlefelt C; Repo JP; Jahkola T; Kauhanen S; Homsy P
J Plast Reconstr Aesthet Surg; 2024 Jan; 88():478-486. PubMed ID: 38101261
[TBL] [Abstract] [Full Text] [Related]
2. pml modulates epigenetic composition of chromatin to regulate expression of pro-metastatic genes in triple-negative breast cancer.
Fracassi C; Ugge' M; Abdelhalim M; Zapparoli E; Simoni M; Magliulo D; Mazza D; Lazarevic D; Morelli MJ; Collas P; Bernardi R
Nucleic Acids Res; 2023 Nov; 51(20):11024-11039. PubMed ID: 37823593
[TBL] [Abstract] [Full Text] [Related]
3. Single-cell combined with bulk-RNA data reveal a pattern related to angiogenesis in breast cancer patients: Individualized medicine.
Zhang W; Yu Y; Yang F
Environ Toxicol; 2024 Feb; 39(2):695-707. PubMed ID: 37647361
[TBL] [Abstract] [Full Text] [Related]
4. Promyelocytic leukemia protein regulates angiogenesis and epithelial-mesenchymal transition to limit metastasis in MDA-MB-231 breast cancer cells.
Vogiatzoglou AP; Spanou S; Sachini N; Drakos E; Nikolaou C; Makatounakis T; Kretsovali A; Papamatheakis J
Mol Oncol; 2023 Oct; 17(10):2090-2108. PubMed ID: 37518985
[TBL] [Abstract] [Full Text] [Related]
5. Evaluation of biosimilar trastuzumab myl-1401O in HER2-positive breast cancer.
Eser K; Sezer E; Erçolak V; İnal A
Am J Manag Care; 2023 Feb; 29(2):e36-e42. PubMed ID: 36811986
[TBL] [Abstract] [Full Text] [Related]
6. Progressive multifocal leukoencephalopathy, advanced ductal breast carcinoma, systemic sclerosis, and checkpoint inhibitors: a therapeutic dilemma.
Baena-Álvarez B; Rodríguez-Jorge F; Beltrán-Corbellini Á; Cortés-Salgado A; De la Puente C; Corral Í
J Neurovirol; 2023 Feb; 29(1):116-119. PubMed ID: 36348234
[TBL] [Abstract] [Full Text] [Related]
7. Clinical application of low-level laser therapy (Photo-biomodulation therapy) in the management of breast cancer-related lymphedema: a systematic review.
Mahmood D; Ahmad A; Sharif F; Arslan SA
BMC Cancer; 2022 Aug; 22(1):937. PubMed ID: 36042421
[TBL] [Abstract] [Full Text] [Related]
8. Accuracy of tumor registry versus pharmacy dispensings for breast cancer adjuvant endocrine therapy.
Haas CB; Bowles EJA; Lee JM; Specht J; Buist DSM
Cancer Causes Control; 2022 Sep; 33(9):1145-1153. PubMed ID: 35796846
[TBL] [Abstract] [Full Text] [Related]
9. A Review of Trastuzumab Biosimilars in Early breast cancer and Real World Outcomes of Neoadjuvant myl-1401O versus Reference Trastuzumab.
Yang C; Khwaja R; Tang P; Nixon N; King K; Lupichuk S
Curr Oncol; 2022 Jun; 29(6):4224-4234. PubMed ID: 35735446
[TBL] [Abstract] [Full Text] [Related]
10. Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis.
Liu T; Liu D; Jin Y; Dong M
Immunopharmacol Immunotoxicol; 2022 Dec; 44(6):809-815. PubMed ID: 35708278
[TBL] [Abstract] [Full Text] [Related]
11. Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer.
Liu J; Wang Y; Tian Z; Lin Y; Li H; Zhu Z; Liu Q; Su S; Zeng Y; Jia W; Yang Y; Xu S; Yao H; Jiang W; Song E
Nat Commun; 2022 May; 13(1):3011. PubMed ID: 35641481
[TBL] [Abstract] [Full Text] [Related]
12. Long-Term Effectiveness of Combined Intermittent Pneumatic Compression Plus Low-Level Laser Therapy in Patients with Postmastectomy Lymphedema: A Randomized Controlled Trial.
Kozanoglu E; Gokcen N; Basaran S; Paydas S
Lymphat Res Biol; 2022 Apr; 20(2):175-184. PubMed ID: 33826415
[No Abstract] [Full Text] [Related]
13. Mutational profiling of micro-dissected pre-malignant lesions from archived specimens.
Nachmanson D; Steward J; Yao H; Officer A; Jeong E; O'Keefe TJ; Hasteh F; Jepsen K; Hirst GL; Esserman LJ; Borowsky AD; Harismendy O
BMC Med Genomics; 2020 Nov; 13(1):173. PubMed ID: 33208147
[TBL] [Abstract] [Full Text] [Related]
14. The promyelocytic leukemia protein isoform pml1 is an oncoprotein and a direct target of the antioxidant sulforaphane (SFN).
Alhazmi N; Pai CP; Albaqami A; Wang H; Zhao X; Chen M; Hu P; Guo S; Starost K; Hajihassani O; Miyagi M; Kao HY
Biochim Biophys Acta Mol Cell Res; 2020 Aug; 1867(8):118707. PubMed ID: 32243901
[TBL] [Abstract] [Full Text] [Related]
15. Type I Interferon Regulates a Coordinated Gene Network to Enhance Cytotoxic T Cell-Mediated Tumor Killing.
Fan JB; Miyauchi S; Xu HZ; Liu D; Kim LJY; Burkart C; Cheng H; Arimoto KI; Yan M; Zhou Y; Győrffy B; Knobeloch KP; Rich JN; Cang H; Fu XD; Zhang DE
Cancer Discov; 2020 Mar; 10(3):382-393. PubMed ID: 31974171
[TBL] [Abstract] [Full Text] [Related]
16. Intrinsically Disordered SRC-3/AIB1 Protein Undergoes Homeostatic Nuclear Extrusion by Nuclear Budding While Ectopic Expression Induces Nucleophagy.
Cabrita MA; Renart LI; Lau R; Pratt MAC
Cells; 2019 Oct; 8(10):. PubMed ID: 31635050
[TBL] [Abstract] [Full Text] [Related]
17. Long-term prognostic effect of hormone receptor subtype on breast cancer.
Hwang KT; Kim J; Jung J; Kim BH; Park JH; Jeon SY; Hwang KR; Roh EY; Park JH; Kim SJ
Breast Cancer Res Treat; 2020 Jan; 179(1):139-151. PubMed ID: 31595365
[TBL] [Abstract] [Full Text] [Related]
18. Targeting pml in triple negative breast cancer elicits growth suppression and senescence.
Arreal L; Piva M; Fernández S; Revandkar A; Schaub-Clerigué A; Villanueva J; Zabala-Letona A; Pujana M; Astobiza I; Cortazar AR; Hermanova I; Bozal-Basterra L; Arruabarrena-Aristorena A; Crespo JR; Valcarcel-Jimenez L; Zúñiga-García P; Canals F; Torrano V; Barrio R; Sutherland JD; Alimonti A; Martin-Martin N; Carracedo A
Cell Death Differ; 2020 Apr; 27(4):1186-1199. PubMed ID: 31570853
[TBL] [Abstract] [Full Text] [Related]
19. Promyelocytic Leukemia (pml) gene regulation: implication towards curbing oncogenesis.
Datta N; Islam S; Chatterjee U; Chatterjee S; Panda CK; Ghosh MK
Cell Death Dis; 2019 Sep; 10(9):656. PubMed ID: 31506431
[TBL] [Abstract] [Full Text] [Related]
20. Mad1 destabilizes p53 by preventing pml from sequestering MDM2.
Wan J; Block S; Scribano CM; Thiry R; Esbona K; Audhya A; Weaver BA
Nat Commun; 2019 Apr; 10(1):1540. PubMed ID: 30948704
[TBL] [Abstract] [Full Text] [Related]
[Next]
